Royalty Pharma 10-Q 10 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 03, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'REPROS THERAPEUTICS INC.	'
Entity Central Index Key	'0000897075	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Trading Symbol	'RPRX	'
Entity Common Stock, Shares Outstanding	'	24,276,173

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets	'	'
Cash and cash equivalents	$53,084	$75,807
Prepaid expenses and other current assets	264	189
Total current assets	53,348	75,996
Fixed assets, net	42	75
Other assets, net	3,360	2,906
Total assets	56,750	78,977
Current Liabilities	'	'
Accounts payable	2,574	2,966
Accrued expenses	402	586
Total current liabilities	2,976	3,552
Commitments and contingencies (note 6)	'	'
Stockholders' Equity	'	'
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding	0	0
Common Stock, $.001 par value, 75,000,000 shares authorized, 24,113,784 and 23,125,565 shares issued, respectively and 24,001,434 and 23,013,215 shares outstanding, respectively	24	23
Additional paid-in capital	317,387	314,405
Cost of treasury stock, 112,350 shares	-1,380	-1,380
Deficit accumulated during the development stage	-262,257	-237,623
Total stockholders' equity	53,774	75,425
Total liabilities and stockholders' equity	$56,750	$78,977

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	24,113,784	23,125,565
Common Stock, shares outstanding	24,001,434	23,013,215
Treasury stock, shares	112,350	112,350
Undesignated Preferred Stock [Member]	'	'
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, issued	0	0
Preferred Stock, outstanding	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		325 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Revenues	'	'	'	'	'
Licensing fees	$0	$0	$0	$0	$28,755
Product royalties	0	0	0	0	627
Research and development grants	0	0	0	0	1,219
Interest income	2	3	7	6	16,318
Gain on disposal of fixed assets	0	0	0	0	102
Other Income	0	0	0	0	1,003
Total revenues and other income	2	3	7	6	48,024
Expenses	'	'	'	'	'
Research and development	6,107	4,786	20,882	17,132	239,053
General and administrative	1,277	1,215	3,759	3,453	61,497
Other Expense	0	0	0	0	388
Total expenses	7,384	6,001	24,641	20,585	300,938
Loss from continuing operations	-7,382	-5,998	-24,634	-20,579	-252,914
Loss from discontinued operations	0	0	0	0	-1,828
Gain on disposal of discontinued operation	0	0	0	0	939
Net loss before cumulative effect of change in accounting principle	-7,382	-5,998	-24,634	-20,579	-253,803
Cumulative effect of change in accounting principle	0	0	0	0	-8,454
Net loss	($7,382)	($5,998)	($24,634)	($20,579)	($262,257)
Loss per share - basic and diluted:	($0.32)	($0.26)	($1.06)	($1.03)	'
Weighted average shares used in loss per share calculation:	'	'	'	'	'
Basic	23,347	23,006	23,162	20,066	'
Diluted	23,347	23,006	23,162	20,066	'

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Deficit Accumulated During the Development Stage
In Thousands, except Share data
Beginning Balance at Dec. 31, 2012	$23,034	$17	$234,299	($1,380)	($209,902)
Beginning Balance (in shares) at Dec. 31, 2012	'	17,272,505	'	112,350	'
Stock based option compensation	2,258	0	2,258	0	0
Issuance shares of common stock for the cashless exercise of Series A Warrants	0	1	-1	0	0
Issuance shares of common stock for the cashless exercise of Series A Warrants (in shares)	'	871,634	'	0	'
Issuance shares of common stock for the cashless exercise of Series B Warrants	0	1	-1	0	0
Issuance shares of common stock for the cashless exercise of Series B Warrants (in shares)	'	614,564	'	0	'
Exercise of 42,849 Series B Warrants to purchase common stock for cash @ $2.49 per share	107	0	107	0	0
Exercise of 42,849 Series B Warrants to purchase common stock for cash @ $2.49 per share(in shares)	'	42,849	'	0	'
Issuance of 4,312,500 shares of common stock at $19.00 per share, net of offering costs of $5.2 million	76,764	4	76,760	0	0
Issuance of 4,312,500 shares of common stock at $19.00 per share, net of offering costs of $5.2 million(in shares)	'	4,312,500	'	0	'
Issuance common stock for the cashless exercise of stock options	0	0	0	0	0
Issuance common stock for the cashless exercise of stock options (in shares)	'	5,407	'	0	'
Exercise of stock options to purchase common stock for cash	47	0	47	0	0
Exercise of stock options to purchase common stock for cash (in shares)	'	2,500	'	0	'
Net loss	-20,579	0	0	0	-20,579
Ending Balance at Sep. 30, 2013	81,631	23	313,469	-1,380	-230,481
Ending Balance (in shares) at Sep. 30, 2013	'	23,121,959	'	112,350	'
Beginning Balance at Dec. 31, 2013	75,425	23	314,405	-1,380	-237,623
Beginning Balance (in shares) at Dec. 31, 2013	'	23,125,565	'	112,350	'
Stock based option compensation	2,836	0	2,836	0	0
Issuance shares of common stock for the cashless exercise of Series A Warrants	0	1	-1	0	0
Issuance shares of common stock for the cashless exercise of Series A Warrants (in shares)	'	562,222	'	0	'
Issuance shares of common stock for the cashless exercise of Series B Warrants	0	0	0	0	0
Issuance shares of common stock for the cashless exercise of Series B Warrants (in shares)	'	329,753	'	0	'
Issuance common stock for the cashless exercise of stock options	0	0	0	0	0
Issuance common stock for the cashless exercise of stock options (in shares)	'	72,910	'	0	'
Exercise of stock options to purchase common stock for cash	147	0	147	0	0
Exercise of stock options to purchase common stock for cash (in shares)	'	23,334	'	0	'
Net loss	-24,634	0	0	0	-24,634
Ending Balance at Sep. 30, 2014	$53,774	$24	$317,387	($1,380)	($262,257)
Ending Balance (in shares) at Sep. 30, 2014	'	24,113,784	'	112,350	'

CONSOLIDATED_STATEMENTS_OF_STO1

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Issuance of shares of common stock for the cashless exercise of Series A Warrants stock options	562,523	872,133
Issuance of shares of common stock for the cashless exercise of Series B Warrants stock options	380,101	716,463
Issuance of shares of common stock for the cashless exercise of stock options	98,329	8,332
Exercise of stock option to purchase common stock for cash, share price	'	$18.74
Sale Of Stock Price Per Shares	'	$19
Issuance of shares of common stock, offering costs	'	$5.20
Series B [Member]	'	'
Exercise of stock option to purchase common stock for cash, share price	'	$2.49
Maximum [Member]	'	'
Exercise of stock option to purchase common stock for cash, share price	9.6	'
Minimum [Member]	'	'
Exercise of stock option to purchase common stock for cash, share price	1.56	'

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		325 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Cash Flows from Operating Activities	'	'	'
Net loss	($24,634)	($20,579)	($262,257)
Gain on disposal of discontinued operations	0	0	-939
Gain on disposal of fixed assets	0	0	-102
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Noncash financing costs	0	0	316
Noncash inventory impairment	0	0	4,417
Noncash patent impairment	0	0	2,614
Noncash other income	0	0	-709
Noncash decrease in accounts payable	0	0	-1,308
Depreciation and amortization	270	177	4,828
Noncash stock-based compensation	2,836	2,258	18,312
Common stock issued for agreement not to compete	0	0	200
Series B Preferred Stock issued for consulting services	0	0	18
Changes in operating assets and liabilities (net effects of purchase of businesses in 1988 and 1994):	'	'	'
Increase in receivables	0	0	-199
Increase in inventory	0	0	-4,447
(Increase) decrease in prepaid expenses and other current assets	-75	213	38
Increase (decrease) in accounts payable and accrued expenses	-439	-532	10,822
Net cash used in operating activities	-22,042	-18,463	-228,396
Cash Flows from Investing Activities	'	'	'
Change in trading marketable securities	0	0	-191
Capital expenditures	0	-63	-2,486
Purchase of other assets	-828	-776	-7,210
Proceeds from sale of PP&E	0	0	225
Cash acquired in purchase of FTI	0	0	3
Proceeds from sale of subsidiary, less $12,345 for operating losses during 1990 phase-out period	0	0	138
Proceeds from sale of the assets of FTI	0	0	2,250
Increase in net assets held for disposal	0	0	-213
Net cash used in investing activities	-828	-839	-7,484
Cash Flows from Financing Activities	'	'	'
Proceeds from issuance of common stock, net of offering costs	0	76,764	284,195
Exercise of stock options & warrants	147	154	1,134
Proceeds from a shareholder transaction	0	0	327
Proceeds from issuance of preferred stock	0	0	23,688
Purchase of treasury stock	0	0	-21,487
Proceeds from issuance of notes payable	0	0	2,839
Principal payments on notes payable	0	0	-1,732
Net cash provided by financing activities	147	76,918	288,964
Net increase (decrease) in cash and cash equivalents	-22,723	57,616	53,084
Cash and cash equivalents at beginning of period	75,807	24,212	0
Cash and cash equivalents at end of period	$53,084	$81,828	$53,084

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Proceeds from sale of subsidiary, operating losses during 1990 phase-out period	$12,345

Organization_Operations_and_Li

Organization, Operations and Liquidity	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Operations and Liquidity	'
	NOTE 1 — Organization, Operations and Liquidity
	Repros Therapeutics Inc. (the “Company,” “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.
	Our primary product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We are developing Androxal® for men of reproductive age with low testosterone levels. Androxal® treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. We have completed all pivotal Phase 3 efficacy studies, including the recently completed, ZA-304 and ZA-305, against an approved testosterone replacement product.
	Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. We completed a dose escalating study to demonstrate both safety and efficacy signals in low oral doses of Proellex® and we are conducting a Phase 2 study in the treatment of endometriosis. Additionally, the Food and Drug Administration has accepted an Investigational New Drug Application for vaginally delivered Proellex®. As a result, we completed a Phase 1/2 vaginal administration study for uterine fibroids.
	Our product development pipeline, with dates as expected as of the date of this report, is summarized in the table below:
	Product Candidate (Indication)	Status	Next Expected Milestone(s)
	Androxal®
	Secondary Hypogonadism	Phase 3	Submit New Drug Application (NDA) (submission timeline to be reassessed based on analysis of November 2014 interactions with FDA)
	Proellex®
	Uterine Fibroids	Phase 2	Initiate a Phase 2B study (vaginal delivery) (Q4 2014)
			Initiate a Phase 2 study (oral delivery) (Q4 2014)
	Endometriosis	Phase 2	Fully enroll Phase 2 study (oral delivery) (H1 2015)
	As of September 30, 2014, we had accumulated losses of $262.3 million, approximately $53.1 million in cash and cash equivalents, and accounts payable and accrued expenses of approximately $3.0 million, in the aggregate. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates through at least the first half of 2016. We continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.

Patents_and_Patent_Application

Patents and Patent Applications	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Patents and Patent Applications	'
	NOTE 2 — Patents and Patent Applications
	As of September 30, 2014, we had approximately $3.4 million in capitalized patent and patent application costs reflected on our balance sheet. Of this amount, $2.0 million relates to Androxal® and $1.4 million relates to Proellex®.
	Should we not continue development of either drug candidate or should the Company not continue as a going concern, the remaining capitalized patent costs may not be recoverable, which would result in charges to operating results in future periods.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Accrued Expenses [Abstract]	'
Accrued Expenses	'
	NOTE 3 — Accrued Expenses
	Accrued expenses consist of the following (in thousands):
		September 30, 2014		December 31, 2013
	Research and development costs	$	193	$	89
	Personnel related costs		48		196
	Patent costs		28		188
	Other		133		113
	Total	$	402	$	586

Loss_Per_Share

Loss Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Loss Per Share	'
	NOTE 4 — Loss Per Share
	Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.
	The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2014 and 2013 (in thousands, except per share amounts):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2014		2013		2014		2013
	Net loss	$	-7,382	$	-5,998	$	-24,634	$	-20,579
	Average common shares outstanding		23,347		23,006		23,162		20,066
	Basic and diluted loss per share	$	-0.32	$	-0.26	$	-1.06	$	-1.03
	Potential common stock of 3,191,426 and 3,975,430 common shares underlying stock options and warrants for the periods ended September 30, 2014 and 2013, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Other potential common stock at September 30, 2014 includes Series A Warrants to purchase 314,614 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 429,704 shares of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering. Other potential common stock at September 30, 2013 includes Series A Warrants to purchase 877,137 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 810,109 shares of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	NOTE 5 – Stock-Based Compensation
	During the three month period ended September 30, 2014, the Compensation Committee of the Company’s Board of Directors approved grants of options to purchase 50,000 shares of our common stock to employees and directors under the 2011 Equity Incentive Plan. All of the options granted during the three month period ended September 30, 2014 vest over a three year period. During the nine month period ended September 30, 2014, the Compensation Committee of the Company’s Board of Directors approved grants of options to purchase 351,000 shares of our common stock to employees under the 2011 Equity Incentive Plan. Of the options granted, 326,000 options vest over a three year period and 25,000 vest over a one year period. Additionally, during the nine month period ended September 30, 2014, 127,080 options either expired or were forfeited.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	NOTE 6 — Commitments and Contingencies
	Therapeutic uses of our Androxal® product candidate are covered in the United States by nine issued U.S. patents and six pending patent applications. Foreign coverage of therapeutic uses of our Androxal® product candidate includes 68 issued foreign patents and 78 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Androxal® (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of anti-estrogen such as clomiphene citrate and others for use in the treatment of disorders related to androgen deficiency. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Court of Appeals for the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. The PTO issued an Ex Parte Reexamination Certificate on April 29, 2013, canceling the rejected claims and confirming the patentability of the remaining claims. Nevertheless, we believe that our development of Androxal® does not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims that may be brought by the holder of such patents in a court of competent jurisdiction in order to develop Androxal® further. Adverse determinations in litigation proceedings could require us to seek licenses which may not be available on commercially reasonable terms, or at all, or subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license Androxal® until such patents expire or are otherwise no longer in force.
	On July 19, 2013, we received a letter from Dr. Harry Fisch threatening to file a lawsuit against us and two of our executive officers (Joseph S. Podolski, President and Chief Executive Officer and Ron Wiehle, Executive Vice President), seeking addition of Dr. Harry Fisch as an inventor on three of our patents, U.S. Patent Nos. 7,173,064, 7,737,185 and 7,759,360, covering therapeutic uses of Androxal®. We believe that these allegations are without merit and on August 2, 2013, we commenced a lawsuit against Dr. Fisch in the U.S. District Court for the Southern District of Texas seeking a declaratory judgment that he should not be added as an inventor to any of these patents. On October 2, 2013, Dr. Fisch filed his answer and counterclaims to our complaint. Dr. Fisch asserted counterclaims seeking correction of inventorship of the three patents at issue to name Dr. Fisch as a co-inventor of the applications leading these patents. Dr. Fisch subsequently stipulated that he does not claim to be a co-inventor of U.S. Patent No. 7,173,064. Dr. Fisch also seeks reasonable attorney’s fees. Discovery closed on September 19, 2014 and summary judgment motions filed by both parties are pending. No hearing date for the motions has been set. We believe there is no merit to Dr. Fisch’s counterclaims and we intend to continue to vigorously defend against them. However, there can be no assurance that we will ultimately be successful in this matter.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	NOTE 7 — Subsequent Events
	On October 15, 2014, 274,739 shares of our common stock were issued for the cashless exercise of 275,019 Series A Warrants.

Organization_Operations_and_Li1

Organization, Operations and Liquidity (Tables)	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Product Development Pipeline	'
	Our product development pipeline, with dates as expected as of the date of this report, is summarized in the table below:
	Product Candidate (Indication)	Status	Next Expected Milestone(s)
	Androxal®
	Secondary Hypogonadism	Phase 3	Submit New Drug Application (NDA) (submission timeline to be reassessed based on analysis of November 2014 interactions with FDA)
	Proellex®
	Uterine Fibroids	Phase 2	Initiate a Phase 2B study (vaginal delivery) (Q4 2014)
			Initiate a Phase 2 study (oral delivery) (Q4 2014)
	Endometriosis	Phase 2	Fully enroll Phase 2 study (oral delivery) (H1 2015)

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Accrued Expenses [Abstract]	'
Accrued Expenses	'
	Accrued expenses consist of the following (in thousands):
		September 30, 2014		December 31, 2013
	Research and development costs	$	193	$	89
	Personnel related costs		48		196
	Patent costs		28		188
	Other		133		113
	Total	$	402	$	586

Loss_Per_Share_Tables

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Calculation of Loss Per Share	'
	The following table presents information necessary to calculate loss per share for the three and nine month periods ended September 30, 2014 and 2013 (in thousands, except per share amounts):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2014		2013		2014		2013
	Net loss	$	-7,382	$	-5,998	$	-24,634	$	-20,579
	Average common shares outstanding		23,347		23,006		23,162		20,066
	Basic and diluted loss per share	$	-0.32	$	-0.26	$	-1.06	$	-1.03

Organization_Operations_and_Li2

Organization, Operations and Liquidity (Product Development Pipeline) (Details)	9 Months Ended
	Sep. 30, 2014
Androxal [Member] | Secondary Hypogonadism [Member]	'
Product Information [Line Items]	'
Status	'Phase 3
Next Expected Milestone(s)	'Submit New Drug Application (NDA) (submission timeline to be reassessed based on analysis of November 2014 interactions with FDA)
Proellex [Member] | Uterine Fibroids 1 [Member]	'
Product Information [Line Items]	'
Status	'Phase 2
Next Expected Milestone(s)	'Initiate a Phase 2B study (vaginal delivery) (Q4 2014) Initiate a Phase 2 study (oral delivery) (Q4 2014)
Proellex [Member] | Endometriosis [Member]	'
Product Information [Line Items]	'
Status	'Phase 2
Next Expected Milestone(s)	'Fully enroll Phase 2 study (oral delivery) (H1 2015)

Organization_Operations_and_Li3

Organization, Operations and Liquidity (Additional Information) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012	Aug. 20, 1987
Product Information [Line Items]	'	'	'	'	'
Deficit accumulated during the development stage	($262,257,000)	($237,623,000)	'	'	'
Cash and cash equivalents	53,084,000	75,807,000	81,828,000	24,212,000	0
Accounts payable and accrued expenses	$3,000,000	'	'	'	'

Patents_and_Patent_Application1

Patents and Patent Applications (Additional Information) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Capitalized patent and patent application costs	$3,360	$2,906
Androxal [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Capitalized patent and patent application costs	2,000	'
Proellex [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Capitalized patent and patent application costs	$1,400	'

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule Of Accrued Liabilities [Line Items]	'	'
Research and development costs	$193	$89
Personnel related costs	48	196
Patent costs	28	188
Other	133	113
Total	$402	$586

Loss_Per_Share_Calculation_of_

Loss Per Share (Calculation of Loss Per Share) (Details) (USD $)	3 Months Ended		9 Months Ended		325 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Net loss	($7,382)	($5,998)	($24,634)	($20,579)	($262,257)
Average common shares outstanding	23,347	23,006	23,162	20,066	'
Basic and diluted loss per share	($0.32)	($0.26)	($1.06)	($1.03)	'

Loss_Per_Share_Additional_Info

Loss Per Share (Additional Information) (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share Disclosure [Line Items]	'	'
Anti-dilutive shares of common stock excluded from computation of earning per share	3,191,426	3,975,430
Series A Warrants [Member]	'	'
Earnings Per Share Disclosure [Line Items]	'	'
Anti-dilutive shares of common stock excluded from computation of earning per share	314,614	877,137
Warrants, exercise price per share	0.01	0.01
Series B Warrants [Member]	'	'
Earnings Per Share Disclosure [Line Items]	'	'
Anti-dilutive shares of common stock excluded from computation of earning per share	429,704	810,109
Warrants, exercise price per share	2.49	2.49

StockBased_Compensation_Additi

Stock-Based Compensation (Additional Information) (Details) (2011 Equity Incentive Plan Member)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	50,000	351,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	'	127,080
Vested Options One [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	326,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'3 years	'3 years
Vested Options Two [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	25,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'1 year

Commitments_and_Contingencies_

Commitments and Contingencies (Additional Information) (Details)	9 Months Ended
	Sep. 30, 2014
Domestic [Member]	'
Commitments and Contingencies [Line Items]	'
Number of patents	9
Number of pending patent applications	6
Foreign [Member]	'
Commitments and Contingencies [Line Items]	'
Number of patents	68
Number of pending patent applications	78
Third Party [Member]	'
Commitments and Contingencies [Line Items]	'
Number of patents	2

Subsequent_Events_Additional_I

Subsequent Events (Additional Information) (Details) (Subsequent Event [Member])	0 Months Ended
	Oct. 15, 2014
Stock Issued During Period, Shares, New Issues	274,739
Series A Warrants [Member]	'
Warrant Exercised	275,019